VividVisions. Legal performance marketing Log in

Oxbryta claims
after the withdrawal.

Pfizer withdrew the sickle cell disease drug Oxbryta (voxelotor) from all markets in September 2024, citing an imbalance in vaso-occlusive crises and fatal events. Litigation is early; we screen claimants against your firm’s criteria.

Discuss a campaign
Serving law firms nationwide

Summary of public information for law firms. Not legal advice.

Delivery models

Three ways to receive Oxbryta cases.

The right model depends on your intake capacity and acquisition economics.

At the inquiry

Qualified leads

Claimants screened against your firm’s Oxbryta criteria, delivered with their responses to your intake team or CRM.

For teams that handle follow-up and conversion.

Discuss qualified leads

At the conversation

Warm transfers

Screened claimants connected directly with your intake team during agreed hours and within your delivery caps.

For teams ready to take a live call.

How live transfers work

At the retainer

Signed retainers

For select programs, acquisition structured around qualified, completed e-signed retainers.

For firms seeking a retained-client model.

About retainer programs

The litigation · October 2026

What firms
should know now.

Litigation moves quickly. We confirm current status, and whether a program fits your firm’s strategy, before launch.

Sources
  1. 2019

    Approval

    Oxbryta received FDA accelerated approval to treat sickle cell disease.

  2. Sep 2024

    Worldwide withdrawal

    Pfizer withdrew all lots worldwide, stating that the overall benefit no longer outweighed the risk, with data suggesting an imbalance in vaso-occlusive crises and fatal events.

  3. 2025–26

    Early litigation

    Individual and class claims have been filed. As of our October 2026 review, no MDL had been created.

Screening

Questions built
from your criteria.

These are the areas Oxbryta screening typically covers. The exact questions and thresholds come from your firm.

Talk through your criteria
  1. Use

    Whether the claimant took Oxbryta, when and for how long.

  2. Events

    Vaso-occlusive crises, hospitalizations or other outcomes your firm accepts, including wrongful death.

  3. Records

    Prescription and medical records available to document use and events.

  4. Representation

    Whether the claimant or family already has an attorney.

Questions

What firms ask
about Oxbryta.

Answers specific to your program are part of the first conversation.

Is there an Oxbryta MDL?

Not as of our October 2026 review. Litigation is at an early stage, and we confirm current status with your firm before launch.

Who are potential claimants?

People with sickle cell disease who took Oxbryta, and families in wrongful death cases, depending on your firm’s criteria.

Can leads include consent documentation?

Where a program requires it, leads can be delivered with a TrustedForm or Jornaya certificate. Call recordings for transfers depend on program support and applicable consent requirements.

Sources

Public sources for this summary.

Summary of public information as of October 2026, for law firms evaluating case acquisition. It is not legal advice, and litigation status changes.

Start a conversation

Let’s look at
your next campaign.

Send the practice area, criteria and volume you have in mind. We’ll talk through the right delivery model and a sensible starting point.

Book a 30-minute intro call

Your inquiry is emailed to our team. This website does not store form entries. Please share business requirements only.

Campaign inquiry

Ready for your email app.

Review the details below. Nothing has been sent.

Open email app

If your email app doesn’t open, copy the inquiry and email info@vividvisions.marketing.

This website

Website privacy

When you send a campaign inquiry, the details you enter are emailed to the VividVisions team. This website does not store form entries. If sending fails, you can instead pass the inquiry to your own email application and choose whether to send it.

This website uses Vercel Web Analytics to count page views and see which pages are read. It does not use cookies or advertising pixels and does not identify individual visitors. Its fonts are served with the website. Hosting and email providers may process technical or message data under their own policies.

This notice covers this corporate website. Consumer campaign pages and claimant forms require separate disclosures appropriate to their data collection and consent processes.

Questions: info@vividvisions.marketing